High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation 

Slides:



Advertisements
Similar presentations
Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated.
Advertisements

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
How to Treat MDS without Stem Cell Transplantation
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors  Mitchell S. Cairo,
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report  Ivana N.
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age Years with Acute Myelogenous Leukemia in First.
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Risk Factors for 30-Day Hospital Readmission following Myeloablative Allogeneic Hematopoietic Cell Transplantation (allo-HCT)  Nelli Bejanyan, Brian J.
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H
Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,
Sabina Kersting, Leo F. Verdonck 
Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
A Meta-Analysis of Unrelated Donor Umbilical Cord Blood Transplantation versus Unrelated Donor Bone Marrow Transplantation in Adult and Pediatric Patients 
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Posttransplant Thrombopoiesis Predicts Survival in Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplantation  Mary J. Ninan, Christopher.
Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation  David A. Jacobsohn, Brad Hewlett, Elaine Morgan,
Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission  Jennifer L. Holter.
Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.
Paul Szabolcs, Donna Niedzwiecki 
Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program  Margaret L.
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
Autologous Stem Cell Transplantation (ASCT) Is Effective Therapy for Older Patients with Non-Hodgkin's Lymphoma (NHL)  Deepa Jagadeesh, MD, MPH, Lisa.
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation  Betul Oran, John E. Wagner, Todd.
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Peripheral Blood Lymphocyte and Monocyte Recovery and Survival in Acute Leukemia Postmyeloablative Allogeneic Hematopoietic Stem Cell Transplant  Mary.
Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia
Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple.
Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.
Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma  Anuj Mahindra, Brian Bolwell, Ronald.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study  Debbie Bates, Brian Bolwell, Navneet.
Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.
Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation  Merav Bar, Weigang Tong, Megan Othus,
Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic.
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia  John Moore, Ian Nivison-Smith,
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older  Vikas Gupta, Andrew Daly,
Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation  Ibrahim.
Favorable Outcomes in Patients with High Donor-Derived T Cell Count after In Vivo T Cell–Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation 
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Blood and Marrow Transplant Handbook
Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic.
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Treatment versus Transplant for Challenging Hematologic Disorders
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.
Transplantation of Unrelated Donor Umbilical Cord Blood for Nonmalignant Diseases: a Single Institution's Experience with 45 Patients  Tang-Her Jaing,
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
In Memoriam: E. Donnall Thomas
Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation.
Presentation transcript:

High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation  William Blum, Brian J. Bolwell, Gary Phillips, Sherif S. Farag, Thomas S. Lin, Belinda R. Avalos, Sam L. Penza, Guido Marcucci, John C. Byrd, Matt E. Kalaycio, Ronald M. Sobecks, Brad Pohlman, Stacey Brown, Patrick J. Elder, Edward A. Copelan  Biology of Blood and Marrow Transplantation  Volume 12, Issue 1, Pages 61-67 (January 2006) DOI: 10.1016/j.bbmt.2005.06.004 Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Overall survival was dichotomized in 4 different ways. A, Dichotomization is based on a cutoff of circulating blasts <5000/μL. B, Dichotomization is based on <20% bone marrow blasts. C, Dichotomization is based on whether the subject had any circulating blasts. D, Dichotomization is based on whether the patient had ≤2 prior treatments. All 4 Kaplan-Meier survival curves were tested for equality by using a log-rank test. The P values are shown on each graph. Biology of Blood and Marrow Transplantation 2006 12, 61-67DOI: (10.1016/j.bbmt.2005.06.004) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions